CARE reaffirms A+ rating to IOL Chemicals and Pharmaceuticals
The 'A+' rating reflects IOL's robust business model, diversified product portfolio
The 'A+' rating reflects IOL's robust business model, diversified product portfolio
Cipla has a robust governance model focused on sustainability
With this, the number of marketing approvals for its oncology products across 75 countries has gone up to 503
Intent to start at least 5 innovative Phase 3 vaccine programs by 2025
The company will submit its comprehensive response on these observations to the USFDA
The product will be produced at the Eugia Pharma Specialities, Unit-I, Medchal, Malkajgiri District, Telangana, India
The company will supply materials to all global regions including Asia such as China, India, Europe, and the U.S.
The investment is part of Croda’s continuing commitment to develop high performance pharmaceutical ingredients and technologies for life sciences.
Subscribe To Our Newsletter & Stay Updated